Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 24;14(21):5205.
doi: 10.3390/cancers14215205.

Role of Immunotherapy in the Treatment of Cancer: A Systematic Review

Sia Pei Ling  1 , Long Chiau Ming  1   2 , Jagjit Singh Dhaliwal  1 , Madhu Gupta  3 , Chrismawan Ardianto  2 , Khang Wen Goh  4 , Zahid Hussain  5 , Naeem Shafqat  1
Affiliations
Review

Role of Immunotherapy in the Treatment of Cancer: A Systematic Review

Sia Pei Ling et al. Cancers (Basel). .

Abstract

Tremendous progress has been made in cancer research over the years, and, as a result, immunotherapy has emerged as an important therapy for the treatment of cancer, either as a stand-alone treatment or in conjunction with other cancer therapies. Immunotherapy has demonstrated encouraging outcomes and offers a viable strategy for not only enhancing the quality of life but also dramatically boosting the overall survival rate of cancer patients. The objective of this systematic review was to assess the efficacy of immunotherapy in the treatment of cancer. Databases such as PubMed and Science Direct were searched from their inception until September 2021, using the following keywords: cancer immunotherapy, cancer recurrence, cancer treatment options, and cancer therapies. The systematic review was conducted in accordance with the PRISMA protocol. There were a total of 599 articles; however, after applying the inclusion and exclusion criteria, the final review ended up with 34 publications. In conclusion, the studies have demonstrated that immunotherapy is a viable alternative treatment option for patients with recurrent or metastatic cancer, since the overall survival rate and progression-free survival rate were shown to be successful.

Keywords: antineoplastic agent; biological therapy; breast cancer; cancer cell; glioblastoma; immunomodulation; medicine; neoplasm; non-small cell lung cancer; preventable death.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow chart.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Xiaomei M., Herbert Y. Cancer Issue: Global Burden of Cancer. Yale J. Biol. Med. 2006;79:85. - PMC - PubMed
    1. Arruebo M., Vilaboa N., Sáez-Gutierrez B., Lambea J., Tres A., Valladares M., González-Fernández Á. Assessment of the Evolution of Cancer Treatment Therapies. Cancers. 2011;3:3279–3330. doi: 10.3390/cancers3033279. - DOI - PMC - PubMed
    1. Whitaker K. Earlier diagnosis: The importance of cancer symptoms. Lancet Oncol. 2019;21:6–8. doi: 10.1016/S1470-2045(19)30658-8. - DOI - PubMed
    1. Borghaei H., Smith M.R., Campbell K.S. Immunotherapy of cancer. Eur. J. Pharmacol. 2009;625:41–54. doi: 10.1016/j.ejphar.2009.09.067. - DOI - PMC - PubMed

LinkOut - more resources